<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01669343</url>
  </required_header>
  <id_info>
    <org_study_id>AI Host Factors</org_study_id>
    <nct_id>NCT01669343</nct_id>
  </id_info>
  <brief_title>Aromatase Inhibitor Host Factors Study</brief_title>
  <official_title>Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine how key patient factors, including body size affect
      how well letrozole suppresses circulating estrogen levels.

      This study has two components: (1) Part A - an observational phase to evaluate the impact of
      vitamin D and obesity on estrogen suppression in post-menopausal women already receiving
      letrozole treatment, and (2) Part B - an interventional phase for women with body mass index
      (BM) &gt; 25 kg/m2.

      If BMI or other patient factors reduce the effectiveness of letrozole, modifications to
      treatment recommendations and studies to test higher dosing of letrozole may be needed to
      maximize the benefit of this treatment and minimize the risk of the breast cancer coming
      back.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Estradiol from Baseline to day 29</measure>
    <time_frame>Baseline and day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Estradiol from Baseline to day 58</measure>
    <time_frame>Baseline and day 58</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Letrozole</measure>
    <time_frame>baseline, day 29 and day 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine Symptoms</measure>
    <time_frame>baseline, day 29 (end of part A) and day 58 (end of part B)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Musculoskeletal Symptoms</measure>
    <time_frame>baseline (day 1), day 29 (end of part A) and day 58 (end of part B)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part A letrozole 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>letrozole 2.5 mg tablet,once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B letrozole 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>letrozole 2.5 mg tablet, two tablets,once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Active Comparator Arm receives 2.5 mg letrozole and Experimental Arm receives 5.0 mg letrozole</description>
    <arm_group_label>Part A letrozole 2.5 mg</arm_group_label>
    <arm_group_label>Part B letrozole 5.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal female patients

          -  histological confirmed diagnosis of estrogen receptor and/or progesterone receptor
             positive breast cancer (Stage I-III) who have completed local therapy

          -  Currently prescribed and taking letrozole 2.5 mg daily for a minimum of 3 months

          -  Willing to provide written informed consent to participate

          -  for the experimental arm: all of the above and body mass index (BMI) &gt; 25 kg/m2

        Exclusion Criteria:

          -  Known abnormal liver or renal function defined by:

               1. Serum Creatinine &gt; 1.25 times institutional upper limit of normal (ULN) or
                  Calculated Creatinine Clearance &lt; 40 mL/min

               2. Serum Bilirubin, AST or ALT &gt; 1.5 times ULN

          -  Presence of persistent local or known metastatic cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srikala Sridhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's College Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2012</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aromatase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

